Search Results for "Where To Buy Pirfenidone"

13:46 EDT 28th July 2015 | BioPortfolio

Matching Channels

None

Matching News

IPF Guidelines Add New Agents

(MedPage Today) -- Pirfenidone and nintedanib get conditional recommendation.

Continue Tx in IPF Even With Decline

(MedPage Today) -- Patients with idiopathic pulmonary fibrosis who have an early decline in FVC while on pirfenidone should stay on treatment.

Boehringer eyes Ofev success in IPF and beyond

Experts say the launch of Boehringer Ingelheim’s new treatment for idiopathic pulmonary fibrosis (IPF) offers stiff competition to Roche’s Esbriet that serve to ultimately benefit patients. Boehri...

Concert Pharmaceuticals Receives $50 Million Payment from Auspex Pharmaceuticals

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has received a payment of $50.2 million from Auspex Pharmaceuticals, Inc. The payment is pursuant to a ...

Boehringer's lung drug to hit EU markets

The prospects for patients in Europe with the rare debilitating and fatal lung disease idiopathic pulmonary fibrosis are looking up with the imminent market arrival of Boehringer Ingelheim's Ofev.Ofev...

Moerae Matrix, Inc. (Moerae) Appoints Bill Bradford, M.D., PhD, as Chief Medical Officer

MORRISTOWN, N.J., July 6, 2015 /PRNewswire/ -- Moerae Matrix, a clinical stage biotechnology company focused on developing novel therapeutics that target inflammation and fibrosis, today announced the...

Actemra a breakthrough for systemic sclerosis, says FDA

Roche's rheumatoid arthritis (RA) drug Actemra/RoActemra could be an important therapy for the life-threatening autoimmune disease systemic sclerosis (SSc), according to the US FDA.The US regulator ha...

Physician Views: Idiopathic pulmonary fibrosis – on the cusp of a revolution; how will forthcoming approvals shape the treatment and development landscapes?

Recently added to the BioPortfolio report store, Physician Views: Idiopathic pulmonary fibrosis – on the cusp of a revolution; how will forthcoming approvals shape the treatment and development lan...

Matching PubMed Articles

Pirfenidone inhibits proliferation, arrests the cell cycle, and downregulates heat shock protein‑47 and collagen type I in rat hepatic stellate cells in vitro.

Pirfenidone (esbiret) is an established anti‑fibrotic and anti‑inflammatory drug used to treat idiopathic pulmonary fibrosis. In the present study, the dose‑dependent effects of pirfenidone on t...

Determination and pharmacokinetic study of pirfenidone in rat plasma by UPLC-MS/MS.

A rapid, sensitive and selective ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) was developed and validated for the determination and pharmacokinetic investigation of pi...

Idiopathic pulmonary fibrosis: the turning point is now!

treatment options, which now have become available for patients. In face of the newly available therapies we present an update on the pathophysiology and epidemiology of IPF. We discuss the typical cl...

Sensitivity Analyses of the Change in Forced Vital Capacity in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.

Forced vital capacity (FVC) outcomes in clinical trials in idiopathic pulmonary fibrosis (IPF) can be substantially influenced by the analytic methodology and the handling of missing data. We conducte...

Intraindividual Response to Treatment with Pirfenidone in Idiopathic Pulmonary Fibrosis.

Search Whole site using Google

Loading

Advertisement
 
Advertisement
 
Advertisement Advertisement